Company news
Cdt Equity Inc. (NASDAQ:CDT) news
Cdt Equity Inc. news releases on 6ix. Latest, Sep 29, 2026: CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
Press releases & updates
CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
September 28, 2026
CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
September 18, 2026
CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health
September 10, 2026
CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
September 2, 2026
CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth
September 1, 2026
CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market
August 25, 2026
CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion
August 3, 2026
CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane
July 20, 2026
CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form Development
June 26, 2026
CDT Notes Strategic Investment into Sarborg and Expansion into Quantum Computing
June 18, 2026
CDT Equity Announces Debt Update and New Loan Facility
June 16, 2026
CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter
May 28, 2026
CDT Announces Canadian Patent for AZD5904 in Male Infertility
May 27, 2026
CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions
May 6, 2026
CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery
April 15, 2026
CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
March 25, 2026
CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy
March 23, 2026
CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth
March 17, 2026
CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent
March 4, 2026
CDT Positions for Transformational Growth
March 4, 2026
CDT Equity Notes Sarborg Expansion into Bacteria and Agrochemicals
February 24, 2026
CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy
February 20, 2026
CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy
January 1, 2026
CDT Equity Increases Bitcoin Holding
October 16, 2025
CDT Equity Inc. Announces Reverse Stock Split
October 9, 2025
CDT Board Authorizes Adoption of Cryptocurrency Treasury Reserve Strategy
September 2, 2025
CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy
August 26, 2025
Conduit to Change Name to CDT Equity Inc.
August 5, 2025
Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries
July 6, 2025
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
June 4, 2025
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market
May 22, 2025
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
May 21, 2025
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
May 16, 2025
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
May 9, 2025
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
May 8, 2025
Conduit Pharmaceuticals Announces Leadership Changes
April 16, 2025
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
April 11, 2025
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program
April 10, 2025
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
April 7, 2025
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
March 31, 2025
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
March 19, 2025
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel
March 6, 2025
Conduit Progresses Phase II of its AI Initiative with Sarborg
February 20, 2025
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
February 12, 2025
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note
February 10, 2025
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development
February 6, 2025
Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence
January 27, 2025
Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline
January 21, 2025
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics
December 11, 2024
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
November 20, 2024